Danvers, MA – March 7, 2019 - Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, today announced they have been named the winner of the 2019 CiteAb awards for Life Science Reagent Supplier of the Year and Antibody Validation Initiative, recognizing the company’s efforts in proactively engaging in a number of validation initiatives designed to improve the quality and quantity of data available to researchers.
Antibodies play a critical role in the scientific community. Since its foundation Cell Signaling Technology has historically been at the forefront of rigorous antibody validation utilizing multiple validation methods including positive/negative cell lines as well as knockout models and siRNA based platforms. These methods, combined with parallel validation in multiple applications ensure the quality and consistency of the antibody reagents that the scientific community has grown to appreciate. The result of this effort has yielded a catalog where the majority of CSTs antibodies have been validated using a binary (positive/negative) model with more products and data added every few weeks.
Founded by Dr. Chalmers, Senior Lecturer, the University of Bath in the United Kingdom, and Dave Kelly, Managing Director of Storm Consultancy, CiteAb is a leading life science data provider that helps researchers and their suppliers make more informed decisions by providing a simple way to query antibodies for research. CiteAb’s Life Science Reagent Supplier of the Year is a new award that recognizes the company with the most citations across antibodies, ELISA kits, biochemicals, and instruments, while CiteAb’s Antibody validation initiative award recognizes the most exciting new antibody validation initiative in the sector from 2018.
“Since our inception in 1999, Cell Signaling Technology has used positive and negative models in every application to validate any given antibody,” said Roberto Polakiewicz, chief scientific officer at Cell Signaling Technology. “Through an elaborate collection of methods and validation processes which we routinely use in house, we are able to recommend an antibody for a given application that it will perform when using the protocol that we've specified, guaranteeing increasing the odds that their experiments will be a success.”
“Cell Signaling Technology’s efforts in antibody validation have been extensive and wide reaching,” said Dr. Andrew Chalmers, founder of CiteAb. “By using the very best techniques available, Cell Signaling Technology is able to roll antibody validations out across the majority of its portfolio, making a big difference to validation levels and to the reproducibility of results. Congratulations to all of the team at Cell Signaling Technology.”
In 2018, Cell Signaling Technology committed to enhancing the quality and quantity of validation data and product information available to its customers as part of a larger antibody reproducibility initiative aimed at providing antibody users with additional data and resources to facilitate antibody selection and use. This effort coincides with CST’s anniversary on October 1, 2019, celebrating 20 years of providing researchers with the highest quality, most consistent, and top cited products on the market. For more information please visit www.cellsignal.com.
Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.
Cell Signaling Technology® and CST™ are trademarks of Cell Signaling Technology, Inc.
Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
Director of Marketing Communications
Email: [email protected]
Patrick Farrell, Sniper Public Relations on Behalf of CST
Email: [email protected]